News
On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.
Serena Williams has admitted she is using weight-loss drugs after struggling to shift her post-pregnancy weight. The 23-time ...
4h
Zacks.com on MSNPost Obesity Pill Results Reveal: Buy, Sell or Hold VKTX Stock?
Viking Therapeutics stock sinks after mixed results from its obesity pill trial, raising doubts over safety, tolerability and ...
11h
Pharmaceutical Technology on MSNNovo’s facility issues delay FDA decisions on Regeneron’s Eylea HD
Before Novo arrived as its owner, issues at the Bloomington facility caused a two-month delay for Eylea HD’s FDA approval decision in 2023. In November 2024, the FDA also found quality control lapses ...
The US Food and Drug Administration has approved the weight loss drug semaglutide, marketed as Wegovy, for the treatment of patients with a severe form of liver disease called metabolic associated ...
Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...
5h
ADWEEK on MSNSerena Williams Goes Public With GLP-1 Use in Ro's Push to Normalize Weight Loss Drugs
Terence Stamp, best known for his role playing the villain General Zod in the blockbuster films Superman and Superman II, has ...
CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...
3h
Everyday Health on MSNThe 11 Best Sites to Buy GLP-1 Weight Loss Medications Online, Reviewed by Experts in 2025
Discover the top 11 websites to buy GLP-1 weight loss medications online. Our expert-reviewed guide helps you find safe and reliable options for your needs.
In April 2025 , Northstrive Biosciences announced it received preliminary feedback from the FDA on its planned Type B pre-IND ...
Ascendis Pharma's TransCon platform shows promise, but challenges with rollout, competition, and execution risks lead to a Hold rating.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results